COMMUNIQUÉS West-GlobeNewswire

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
09/09/2026
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient [...]
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
09/09/2026
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in [...]
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
09/09/2026
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the [...]
Zoher F. Kapasi, PhD, PT, Named Provost of Thomas Jefferson University
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Thomas Jefferson University has announced the appointment of Zoher F. Kapasi, PhD, PT, as its next Provost effective Nov. 1, 2026. With extensive experience in higher [...]
Dark Horse Consulting Group Marks the Opening of Its Shanghai Office with Ribbon Cutting Ceremony
09/09/2026
WALNUT CREEK, Calif. and SHANGHAI, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (DHCG) marked the opening of its Shanghai office with a ribbon cutting ceremony celebrating Dark Horse Consulting China. [...]
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
09/09/2026
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced that the US Food and Drug Administration (FDA) has granted [...]
Trethera Congratulates Board Director Dr. Timothy R. Donahue on Appointment to Senior Leadership Roles at Weill Cornell Medicine and NewYork-Presbyterian
09/09/2026
LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, today congratulated [...]
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
09/09/2026
Nantes, France, September 9, 2026 – 6pm CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the “Company”) welcomes the announcement by its licensee Veloxis Pharmaceuticals, Inc. that the first patient [...]
OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
09/09/2026
Nantes, le 9 septembre 2026 – 18h00 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo : OSE) (la « Société ») se félicite de l’annonce de son partenaire Veloxis Pharmaceuticals, Inc. relative au traitement [...]
Fast Company Names Visory Health to Its 2026 Best Workplaces for Innovators List
09/09/2026
The company’s collaborative culture and commitment to empowering employees earned the prestigious recognition ESTERO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Visory Health , a top-three prescription discount card [...]
Quetzal Therapeutics Appoints Harindra R. Abeysinghe, Ph.D., as Chief Regulatory and Quality Officer
09/09/2026
CHICAGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare diseases, including hematologic malignancies, today announced the appointment of [...]
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
09/09/2026
Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centers ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- [...]
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
09/09/2026
Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) [...]
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
09/09/2026
Management to Highlight Growing Commercial Momentum of Arbli ™ and the Commercial Launch of REZENOPY ™ COMMACK, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding [...]
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
09/09/2026
Submission package includes Method Comparison Study, which delivered accuracy above 98%, sensitivity above 94%, and 100% specificity across three independent U.S. clinical sites NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE [...]
Syncromune® Presents SYNC-T™ Therapy: Image-Guided Cryolysis and Intratumoral Immunotherapy at CIRSE 2026
09/09/2026
Invited speaker, Stephen Kee, M.D. reviews SYNC-T™ Therapy SV-102 mechanism, previously reported Phase 1 findings and ongoing Phase 2 LEGION-100 trial in metastatic prostate cancer FORT LAUDERDALE, Fla. and WEST DES [...]
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
09/09/2026
Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe FREMONT, Calif., and HAMBURG, Germany, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sysmex Europe SE , a [...]
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
09/09/2026
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the [...]
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
09/09/2026
Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across Australia MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ( [...]

Pages